Background: Tenofovir (TFV) is an effective and widely used treatment for both HIV and hepatitis B virus infection. However, it’s use in some patients leads to proximal renal tubular dysfunction (PRTD). We aimed to determine the association between polymorphisms in genes encoding drug transporters and PRTD in Thai patients treated with TFV. Methodology: PRTD was defined as the presence of at least 2 of the following: phosphaturia (total excretion of phosphate >1200 mg per day, or renal tubular reabsorption of phosphate (TmP/GFR) <2.6 mg/dL), uricosuria (FE of uric acid >15%), or non-diabetic glucosuria (urine glucose >300 mg per day or positive urine glucose with plasma glucose <120 mg/gL). Nine single nucleotide polymorphism (SNPs) in the ABCC2, ABCC4, ABCC10, and SCL22A6 genes were determined in 358 Thais taking TFV-based antiretroviral regimens. Genotypes were determined by allelic discrimination using the Tagman 5′- nuclease assay. Associations between genotypes, subject demographic, disease and treatment characteristics and PRTD were analysed by univariate and stepwise multivariate logistic regression Results: Out of 358, 67 (18.7%) patients met the criteria of PRTD. After adjusting for age and a history of diabetes, multivariate analysis demonstrated a significant association between PRTD and genotype CC at position 24 (adjusted odds ratio [OR] 2.38; 95% confidence interval [CI] 1.28-4.45, P=0.006); genotype GG at position 1249 (OR 3.54; 95%CI 1.18-10.59, P=0.024) and genotype CC or CT at position 2759 (OR 2.56; 95%CI 1.26-5.21, P=0.009). Conclusions: We found a significant association between SNPs in ABCC2 and ABCC10 and TFV-induced proximal tubular dysfunction in an Asian population. Pharmacogenetic factors may play a role in the risk of renal toxicity associated with the use of TFV. Close monitoring of renal function is warranted in TFV-treated patients with these SNPs.